Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Revalesio Corporation
- Target Recruit Count
- 82
- Registration Number
- NCT04693715
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
๐บ๐ธThe Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธHouston Methodist Hospital, Houston, Texas, United States
Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Revalesio Corporation
- Target Recruit Count
- 140
- Registration Number
- NCT02988297
Study of Electro-kinetically Modified Water for the Treatment of Pain Associated With Endometriosis
Not Applicable
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Revalesio Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT02523794
- Locations
- ๐บ๐ธ
Madigan Army Medical Center, Tacoma, Washington, United States
Pilot Study of RNS60 in Allergen-induced Bronchoconstriction
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- Revalesio Corporation
- Registration Number
- NCT02497222
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
Systemic Bioactivity of Inhaled Nebulized RNS60
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-07-07
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- Revalesio Corporation
- Target Recruit Count
- 56
- Registration Number
- NCT02490865
- Locations
- ๐ฌ๐ง
Surrey Clinical Research Centre, Guildford, Surrey, United Kingdom
Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2016-12-09
- Lead Sponsor
- Revalesio Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT02422121
- Locations
- ๐ฌ๐ง
Quintiles Drug Research Unit at Guy's Hospital, London, United Kingdom
Study of RNS60 on Pain and Function After Hip Labral Repair
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Revalesio Corporation
- Registration Number
- NCT02005523
Study of RNS60 on Pain and Function After Knee Anterior Cruciate Ligament Surgery
Phase 2
Withdrawn
- Conditions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Revalesio Corporation
- Registration Number
- NCT01922427
Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2012-10-25
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Revalesio Corporation
- Registration Number
- NCT01714089
- Locations
- ๐บ๐ธ
Mt. Sinai School of Medicine, New York, New York, United States
Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Revalesio Corporation
- Target Recruit Count
- 65
- Registration Number
- NCT01511302
- Locations
- ๐บ๐ธ
California Allergy and Asthma, Los Angeles, California, United States
๐บ๐ธAxis Clinical Trials, Los Angeles, California, United States
๐บ๐ธWest Coast Clinical Trials, Costa Mesa, California, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath